The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
Official Title: A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Study ID: NCT01108445
Brief Summary: To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
Detailed Description: This will be an international (USA, Canada, and UK) open-label, outpatient, multicenter, randomized study of treatment with RAD001 (everolimus (Afinitor®) or sunitinib (Sutent®) in subjects with mRCC and non-clear cell histology. Special emphasis is placed on papillary and chromophobe histologies while sarcomatoid clear cell variants, medullary, and collecting duct carcinomas will be excluded (see eligibility). Subjects may continue receiving study drugs until disease progression, unacceptable toxicities, or withdrawal of consent, for a maximum of 24 months. Continuation of study assigned treatment will be allowed beyond 24 months at the discretion of the sponsor. Stratification variables will include histology (papillary vs. chromophobe) and Motzer risk criteria (0, 1-2, and 3). Tumor progression will be assessed locally and by independent review, in strict accordance with Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria measured every 12 weeks. At the time of progression, subjects will be taken off study other than simple administrative mortality follow-up. Primary pathologic samples and plasma/urine angiokine levels at baseline and over time will be collected and stored centrally for biomarker analysis.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Chicago, Chicago, Illinois, United States
Indiana University Melvin and Bran Simon Cancer Center, Indianapolis, Indiana, United States
Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States
Washington Univ in St. Louis-School of Medicine, Saint Louis, Missouri, United States
Duke Univeristy Medical Center, Durham, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
Oregon Health & Science University, Portland, Oregon, United States
SCRI, Nashville, Tennessee, United States
The Vanderbilt Clinic, Henry-Joyce Cancer Center, Nashville, Tennessee, United States
BC Cancer Agency, Vancouver, British Columbia, Canada
CancerCare Manitoba, Med Onc, Dept Hem and Onc, Winnipeg, Manitoba, Canada
London Health Sciences Center, London, Ontario, Canada
Cambridge Cancer Trials Centre, Cambridge, England, United Kingdom
The Royal Marsden NHS, London, England, United Kingdom
The Christie Hospital NHS, Manchester, England, United Kingdom
Weston Park Hospital, Sheffield, England, United Kingdom
Churchill Hospital, Headington, Oxford, United Kingdom
Beatson West Scotland Cancer Centre, Glasgow, Scottland, United Kingdom
Name: Andrew Armstrong, MD, ScM
Affiliation: Duke University
Role: PRINCIPAL_INVESTIGATOR